Saturday, April 29, 2017
10:00 am – 2:00 pm
nquiries can also be made at 1-800-882-9539
The National Prescription Drug Take Back Day aims to provide a safe, convenient, and responsible means of disposing of prescription drugs, while also educating the general public about the potential for abuse and medications.
“Innovation Belongs In Every Moment” is this year’s theme at the Regional Annual Conference.
In partnership with the Hemophilia and Thrombosis Treatment Center at Rady Children’s Hospital in San Diego, CIBD co-hosted the 2017 Annual Conference of the Western States Regional Hemophilia Treatment Centers (HTC). Beginning on April 2nd, the two-day conference was held at the Catamaran Resort and Spa and hosted over 200 attendees. Our theme was “Innovation…belongs in every moment.”
The conference brought together clinical and non-clinical staff and supports HTC’s in expanding their professional networks, build clinical skills, and obtain updates on best practices. Attendees represented 14 HTC’s, community based organizations, community clinicians, and industry partners from California, Nevada, Hawaii, and Guam.
To learn more about the work done in our region you can go to: Western States Region IX Network.
If you are interested in learning more about HTC’s and their origin, check out our video on YouTube, entitled, “Blood Roots – Hemophilia Treatment Centers,” produced by the Federal Hemophilia Treatment Centers in Region IX, the University of Colorado Denver|Anschutz Medical Campus, and Oregon Health and Science University:
March 30 is National Doctor’s Day, a time set aside to honor those in the medical profession.
It’s easy to forget just how important, valuable and necessary good doctors are – that is, until you get ill or sustain an injury. CIBD would like to highlight our hard-working doctors, and recognize the long hours they work, their compassion, and the effort they put into taking care of our patients.
Diane Nugent, MD
President and Founder
Amit Soni, MD
Associate Medical Director
Nina Hwang, MD
Susan Claster, MD
David Buchbinder, MD
Loan Hsieh, MD
Arash Mahajerin, MD
Geetha Putheveetil, MD
Founded in 1999 by Paul Newman and Page Adler, along with a group of individuals. The Painted Turtle opened in 2004 providing camp programs all year round. In 2007, furthered their service by establishing an Outreach Program called The Painted Turtle Outpost. This program brings the fun filled joy of camp to children in hospitals and community events.
The Painted Turtle serves children in California with chronic and life-threatening illnesses. For those who qualify, The Painted Turtle provides these children and their families a camping experience free of charge. To learn more about The Painted Turtle and how to apply, please use the links below or go to thepaintedturtle.org .
KEY FINDINGS: New Method to Detect the Type of Antibodies Linked to Inhibitors Development Among People with Hemophilia A and B
In an article release by the CDC (Center for Disease Control and Prevention), research reports key findings related to the formation of inhibitors (antibodies) in patients who have hemophilia. The study shows that hemophilia A and hemophilia B patients who develop inhibitors are likely to have a specific type of antibody called immunoglobulin G subclass 4, or IgG4. In the event that traditional inhibitor tests do not provide clear results, testing for these antibodies instead may help clarify whether an inhibitor is present.
Inhibitors are antibodies (protein) that prevents or stops infused factor from working. For those with bleeding disorders like hemophilia A and hemophilia B, inhibitors often develop because the body’s immune system identifies the clotting factor as foreign. A blood test called Nijmegen-Bethesda Assay (NBA) is used to diagnose inhibitors.
For some cases, NBA can produce an unclear result as to whether a patient has an inhibitor or not. The CDC researchers have addressed this problem by developing a complementary test. A new method called fluorescence immunoassay (FLI). Blood samples from patients with hemophilia A were use to detect antibodies for factor VIII. As well as blood samples from patient with hemophilia B to detect antibodies for factor IX.
For the complete article: CLICK HERE